Literature DB >> 34989083

Early benefit with empagliflozin in heart failure with preserved ejection fraction: insights from the EMPEROR-Preserved trial.

Javed Butler1, Tariq Jamal Siddiqi1, Gerasimos Filippatos2, João Pedro Ferreira3, Stuart J Pocock4, Faiez Zannad5, Stefan D Anker6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 34989083     DOI： 10.1002/ejhf.2420

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN： 1388-9842            Impact factor:   17.349


× No keyword cloud information.
  4 in total

1.  Time to Clinical Benefit of Dapagliflozin in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Secondary Analysis of the DELIVER Randomized Clinical Trial.

Authors:  Muthiah Vaduganathan; Brian L Claggett; Pardeep Jhund; Rudolf A de Boer; Adrian F Hernandez; Silvio E Inzucchi; Mikhail N Kosiborod; Carolyn S P Lam; Felipe Martinez; Sanjiv J Shah; Akshay S Desai; Sheila M Hegde; Daniel Lindholm; Magnus Petersson; Anna Maria Langkilde; John J V McMurray; Scott D Solomon
Journal:  JAMA Cardiol       Date:  2022-10-03       Impact factor: 30.154

Review 2.  Breakthroughs in the treatment of heart failure with mildly reduced and preserved ejection fraction.

Authors:  Khawaja M Talha; Javed Butler
Journal:  Clin Cardiol       Date:  2022-06       Impact factor: 3.287

Review 3.  Multimodal Strategies for the Diagnosis and Management of Refractory Congestion. An Integrated Cardiorenal Approach.

Authors:  Diana Rodríguez-Espinosa; Joan Guzman-Bofarull; Juan Carlos De La Fuente-Mancera; Francisco Maduell; José Jesús Broseta; Marta Farrero
Journal:  Front Physiol       Date:  2022-07-08       Impact factor: 4.755

Review 4.  Empagliflozin in the treatment of heart failure and type 2 diabetes mellitus: Evidence from several large clinical trials.

Authors:  Bo Liang; Ning Gu
Journal:  Int J Med Sci       Date:  2022-06-21       Impact factor: 3.642
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.